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ABSTRACT
Purpose: To evaluate the prognostic significance and correlation with staging and degree of cell differentiation of the
tumoral expression of the proteins c-erbB-2 and E-cadherin, in patients with colorectal adenocarcinoma. Methods: The
study included 117 patients with an average age of 63.1 years and an average follow-up duration of 28.1 months. The
disease-free interval, survival, incidence of recurrence and specific mortality were evaluated. c-erbB-2 anti-oncoprotein
antibodies (Dako) were utilized via the streptavidin-biotin technique. Samples were considered to be positive for c-erbB-
2 if 10% or more of the tumor cell membranes were stained.The anti-E-cadherin antibodies (Dako), evaluated this protein
and is considered positive, if 50% or more of the cell membranes were stained. Statistical analysis was performed using
Pearson’s chi-squared test, Fisher’s exact test, Kaplan-Meier’s estimator, the log-rank test and Wilcoxon’s test (Breslow
version), setting the level of statistical significance at 5% (p<0.05). Results: 52 of 108 patients studied for c-erbB-2 were
positive  (48,1%), 47 of 93 patients studied for E-cadherin were negative (50,5%). These data do not  express any correlation
with TNM (tumor, node and metastasis) staging and the degree of cell differentiation or with the tumor recurrence rate. The
disease-free interval among patients who were positive for c-erbB-2 and negative for E-cadherin was 68.0 months and did
not differ from those with c-erbB-2 negative and E-cadherin positive ( 55.0 months - p = 0.5510). The average survival
among patients positive for c-erbB-2 and negative for E-cadherin was 75 months without statistical significance difference
with the other group  ( 61 months - p = 0.5256). Specific mortality occurred in 20.0% of the cases and did not correlate with
the expression of c-erbB-2 (p=0,446), E-cadherin (p=0,883). Conclusion: The tumoral expression of c-erbB-2 and E-cadherin
did not demonstrate a correlation with the staging and degree of cell differentiation, and it did not present prognostic value
regarding disease recurrence, disease-free interval, survival and specific mortality among patients with colorectal
adenocarcinoma.
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RESUMO
Objetivo: Avaliação da expressão tumoral das proteínas c-erbB-2 e E-caderina e sua relação  com o prognóstico, estadiamento
e grau de diferenciação celular, em doentes com câncer colo-retal . Métodos: O estudo incluiu 117 doentes com média de
idade de 63.1 anos e com acompanhamento médio de 28.1 meses. O intervalo livre de doença, sobrevida, índice de recidiva
e mortalidade específica foram os parâmetros avaliados. Anticorpos anti-oncoproteína c-erbB-2 (Dako) foram utilizados
pela técnica da estreptavidiva-biotina. Considerou-se como positiva a presença desta proteína quando mais de 10% das
células tumorais estivessem coradas. A proteína E-caderina foi estudada pelo anticorpo anti-E-caderina (Dako), sendo
computada como positiva a amostra que apresentasse 50% ou mais das células coradas. A análise estatística utilizou o
teste do qui-quadrado de Pearson, o teste exato de Fischer, a curva de Kaplan-Meier, o teste de log-rank e o teste de
Wilcoxon ( variante de Breslow),sendo estabelecido nível de significância de 5%( p<0,05). Resultados: 52 de 108 doentes
estudados para c-erbB-2 foram positivos  (48,1%), 47 de 93 doentes estudados para E-caderina foram negativos (50,5%).
Estes dados não mostraram relação com estadiamento TNM (tumor, nódulo e metástase), com o grau de diferenciação
celular e índice de recidiva tumoral. O intervalo livre de doença para os doentes positivos para c-erbB-2 e negativos para
E-caderina foi de 68.0 meses e não diferiu daqueles que foram negativos para c-erbB-2 e positivos para E-caderina ( 55.0
meses - p = 0.5510). A sobrevida média para os doentes positivos para c-erbB-2 e negativos para E-caderina foi 75 meses
sem diferença estatisticamente significante com o outro grupo de comparação( 61 meses - p = 0.5256). A mortalidade
específica foi de 20.0% dos casos e não se correlacionou com a expressão do c-erbB-2 (p=0,446) ou da E-caderina(p=0,883).
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Conclusão: A expressão das proteínas c-erbB-2 e E-caderina em doentes portadores de adenocarcinoma colo-retal não
apresentou correlação com o estadiamento e  grau de diferenciação celular. Não houve da mesma forma relação com o
prognóstico, no que diz respeito ao índice de  recidiva da doença, intervalo livre de doença, sobrevida e mortalidade
específica.
Descritores: Neoplasias colorretais. Marcadores biológicos de tumor. Receptor, erbB-2. Caderinas. Imunohistoquímica. Prognóstico.
Introduction
Although the advances in the surgical treatment of
colorectal cancer have given rise to improvements in
survival among patients with tumors in their initial stages,
treatment of more advanced cancer has not resulted in such
significant improvements in patient survival.
Patients’prognoses have mainly been based on their
anatomopathological staging. However, differences have
been observed among patients within the same
anatomopathological staging group. The significant
differences observed in the evolution of such patients
justify why the search for tumor markers has taken on great
relevance within clinical research. Such markers would
enable the classification of patients into subgroups with
specific markers for staging and prognosis and would thus
assist in the recognition and treatment of new patients with
these same markers, especially in relation to those at Dukes
stages B and C 1. Study of the molecular biology of the
tumor by means of tumor markers could therefore, for
example, assist in the identification of patients with a greater
capacity to benefit from adjuvant therapy at stage III. Thus,
the present study had the objective of evaluating the tissue
expression of the proteins c-erbB-2 and E-cadherin,
separately and in association, and correlating this with the
anatomopathological staging, the degree of cell
differentiation, disease-free interval, disease recurrence rate,
survival and specific mortality, among patients who had
been submitted to surgical resection due to colorectal
adenocarcinoma.
Methods
The study was approved by the Institution Ethics
Committee and  included 117 patients with colorectal
adenocarcinoma undergoing surgical treatment, of whom
53 (45.3%) were male and 64 (54.7%) were female. Their ages
ranged from 30 to 87 years, with an average of 63.1 years.
Among these patients, 90 (76.9%) had been submitted to
surgery that had a curative aim, while in 27 cases (23.1%),
the surgery was considered to be palliative. With regard to
TNM (tumor, node and metastasis) staging, 30 patients were
in stage I (25.6%), 21 in stage II (18.0%), 30 (25.6%) in stage
III and 36 (30.8%) in stage IV. Concerning the degree of cell
differentiation presented, there was predominance of
patients with tumors of grade I (well differentiated - 55
patients - 47.0%) and grade II (moderately differentiated -
60 patients - 51.3%), while grade III (poorly differentiated)
was only seen in two cases (1.7%). The follow-up was
directed towards the disease-free interval, incidence of
recurrence, average survival and specific mortality. The
duration of the patients’ follow-up ranged from 1 to 96
months, with an average of 28.1 months. The biological
samples were fixed in formalin and embedded in paraffin.
Sections of 4 µm in thickness were cut for the
immunohistochemical reaction. These were mounted on
slides that had previously been silanized (3-aminopropyl
triethoxysilane, Sigma A-3648, USA) and were left in a glass
cabinet at 60o C for 24 hours to maximize the adhesion of the
sections. Areas of representative sections were stained
using hematoxylin-eosin to allow identification of regions
of interest within the tumor tissue, for the
immunohistochemical reaction. The streptavidin-biotin-
peroxidase technique was utilized with the following
monoclonal antibodies: c-erbB-2 anti-oncoprotein
antibodies, code 1:485 (Dako, Denmark); and anti-E-
cadherin antibodies, clone NCH-38 (Dako, Denmark). For
the evaluation of the expression of the protein c-erbB-2, the
sections were examined semi-quantitatively under an optical
microscope, with sweeping of the slide at a magnification
of 400x, over at least ten fields. For the analysis of the
immunohistochemical and morphological associations, the
tumors were also classified as positive or negative for c-
erbB-2. They were considered to be positive only when
there was immunological reactivity of the cell membrane
that involved at least 10% of the tumor cells. For the marker
E-cadherin, the slides were also examined under the optical
microscope. Positivity was evaluated via the presence of
brown staining on the cell membrane, and the tumors were
considered to be positive for E-cadherin when such staining
was present in 50% or more of the cells analyzed. The
following were utilized in the statistical analysis: Pearson’s
chi-squared test2, Kaplan-Meier, log-rank test, Wilcoxon’s
test (Breslow version)3, Pearson’s chi-squared test and
Fisher’s test. P <0.05 was considered statistically significant.
Results
Among these patients, 48.1% were positive for c-erbB-
2 (52/108), 50.5% were negative for E-cadherin (47/93) and
24.0% were positive for c-erbB-2 and negative for E-cadherin
(20/83). The expression of the markers did not have a
significant association with TNM (tumor, node and
metastasis) staging and the degree of cell differentiation.
The tumor recurrence rate had no correlation with each
marcher: c-erbB-2 positive (p = 0.815), E-cadherin negative
(p = 0.761), or its association (c-erbB-2 positive and E-
cadherin negative - p = 0.972). The disease-free interval
was 68 months (range: 54.0-83.0) for patients with tumors
that were positive for c-erbB-2 and 67 months (54.0-83.0)
for those negative for c-erbB-2, without a statistical
difference (p =0.9164) (Figure 1). In the case of E-cadherin,
the disease-free interval was 67 months (53.0-81.0) for
patients who are positive and 68 months (54.0-83.0) for those
negative, without a statistical difference (p = 0.9164) (Figure
2). The patients with combination of tumors markers (c-
erbB-2 positive and E-cadherin negative ) the disease-free
interval  was 68.0 months (56.0-80.0), without a significant
difference (p = 0.5510) in relation of no presence of this
association 55.0 months (33.0-76.0) (Figure 3). The average
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survival among patients with tumors that were positive for
c-erbB-2 was 68 months (range: 57.0-83.4) and 73 months
(61.0-84.0) for those negative for c-erbB-2, without a
significant difference (p = 0.9164)(Figure 4). For those
positive for E-cadherin it was 68 months (57.0-83.4), and for
those negative for E-cadherin it was 75 months (62.0-89.0),
without a significant difference (p = 0.9164) (Figure 5). When
the patients show the combination of c-erbB-2 positive  and
E-cadherin negative, the average survival was 75 months
(65.0-88.0), without a significant difference (p = 0.5744) in
relation to patients where there was not this association
(average survival - 61 months - range : 40.0-83.0) (Figure 6).
The specific mortality rate was 20.0% (18/90 patients).
Mortality was associated with positivity for c-erbB-2 in
28.8% (15/35), with p = 0.446; negativity for c-erbB-2 in
35.7% (20/35); positivity for E-cadherin in 32.6% (15/31),
with p = 0.883; and negativity for E-cadherin in 34.0% (16/
31), with p = 0.883. No significant difference was found
between the expression of the biological markers and the
specific mortality.
c-erbB-2 Average Confidence interval
Negative 67.0 53.0 – 81.0
Positive 68.0 54.0 – 83.0
Wilcoxon’s test (Breslow version): p = 0,9164
FIGURE 1 - The correlation between the expression of the
protein c-erbB-2 and the disease-free interval.
E-cadherin Average Confidence interval
Negative 68.0 54.0 – 83.0
Positive 67.0 53.0 – 81.0
Wilcoxon’s test (Breslow version): p = 0,9164
FIGURE 2 - The correlation between the expression of the
protein E-cadherin and the disease-free interval.
c-erbB-2 and E-cadherin Average Confidence interval
Negative for c-erbB-2 and
positive for E-cadherin 55.0 33.0 – 76.0
Positive for c-erbB-2 and
negative for E-cadherin 68.0 56.0 – 80.0
Wilcoxon’s test (Breslow version): p = 0,5510
FIGURE 3 - The disease-free interval in relation to the tumor
expression of both c-erbB-2 and Ecadherin.
c-erbB-2 Average Confidence interval
Negative 73.0 61.0 – 84.0
Positive 68.0 57.0 – 83.4
Wilcoxon’s test (Breslow version): p = 0,9164
FIGURE 4 - Survival curve for the patients in relation to the
tumor expression of c-erbB-2.
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Discussion
Even with improvements in surgical treatment and its
association with adjuvant chemotherapy, colorectal cancer
still causes high mortality today. Hepatic metastases occur
in up to 50% of such patients 4, which justifies the search
for new prognostic markers in relation to this disease.
Histopathological evaluation of the disease, by means of
identifying the degree of tumor invasion, infiltration of the
lymphatic ganglia and distant organs, is utilized for defining
E-cadherin Average Confidence interval
Negative 75.0 62.0 – 89.0
Positive 68.0 57.0 – 83.4
Wilcoxon’s test (Breslow version): p = 0.9164
FIGURE 5 - Survival curve for the patients in relation to the
tumor expression of Ecadherin.
c-erbB-2 and E-cadherin Average Confidence interval
positive for c-erbB-2 and
negative for E-cadherin 75.0 65.0 – 88.0
negative for c-erbB-2 and
positive for E-cadherin 61.0 40.0 – 83.0
Wilcoxon’s test (Breslow version): p = 0.5744
FIGURE 6 - Survival curve for the patients in relation to the
tumor expression of both c-erbB-2 and E-
cadherin.
patients’ prognoses. This procedure allows the patients
who are at advanced stages to be distinguished from those
who are at early stages of the disease 5. The information
obtained from staging using the TNM system, however, is
insufficient for making prognoses for patients who are at
intermediate stages of tumor invasion, as is the case with
patients in stage II, T3-T4N0M0 6. In this group, the TNM
system is incapable of distinguishing which patients may
or may not benefit from having, for example, postoperative
chemotherapy associated with their surgical treatment 7.
Thus, the utilization of tumor markers could improve the
clinical staging of the disease. Among the large numbers of
tumor markers that have been described in the literature, it
was decided to study the proteins c-erbB-2 and E-cadherin.
The correlation between these two tumor markers is believed
to involve hyperexpression of the protein c-erbB-2 caused
by amplification of the c-erbB-2 gene, which would lead to
reduced transcription of the E-cadherin and alpha-2 integrin
genes, with consequent reduction in the expression of the
E-cadherin and alpha-2 integrin proteins, thereby causing
the loss of cell adhesion, tumor progression and metastasis
8, 9. The great controversy in the literature and the lack of
conclusive studies regarding the real prognostic value of
the c-erbB-2 and E-cadherin tumor markers in patients with
colorectal adenocarcinoma gave rise to an interest in
investigating these variables together. This had the aim of
verifying whether they would together acquire some
prognostic value. In this respect, the present study would
take on great relevance. The transmembrane protein c-erbB-
2 is the product of the c-erbB-2 gene. It was identified using
the immunohistochemical technique, through observation
of the brown staining of the tumor cell membrane, by utilizing
anti-c-erbB-2 monoclonal antibodies. The interpretation of
immunohistochemical  findings regarding c-erbB-2 varies
in the literature. The quantity of positive cells needed for
defining a result as positive differs according to the study.
Some authors have considered that tumors were positive
for the c-erbB-2 protein when at least 5% of the tumor cells
were stained 10, while others considered that positivity was
reached with 10% stained 11. In the present study, whenever
slides presented staining of more than 10% of the tumor
cells, they were considered positive for the presence of the
c-erbB-2 protein. Thus, 51.9% of the patients in the sample
studied were positive for the expression of this protein.
This rate is similar to findings in the literature 9,10,11. The
protein E-cadherin was also identified using the
immunohistochemical technique, through observation of
the brown staining of the tumor cell membrane. The cutoff
point for positivity of the expression of E-cadherin varies in
the literature. Some authors have defined that tumor cells
are positive for the expression of E-cadherin, when 90% of
these cells are stained using the immunohistochemical
technique 12,13. Other authors have defined positivity as
80% and 50% of the cells stained, respectively14,  15. Great
diversity in the results obtained using the
immunohistochemical method in colorectal
adenocarcinoma, regarding the expression of E-cadherin,
can be seen in the literature. The detection rates for E-
cadherin have varied from 29% 12 to 79% 15 of patients.
Other studies have obtained results that are similar to each
other, with an E-cadherin detection rate of around 50% of
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the colorectal tumors analyzed 16, 17. In the present study,
patients who presented staining of more than 50% of the
tumor cell membranes were considered to be positive for
the expression of E-cadherin. The detection rate for E-
cadherin expression in the present study was 50.5%, a result
that is in agreement with the latter authors cited above.
There are studies in the literature that have identified a
correlation between expression of the c-erbB- 2 protein and
the Dukes classification system18,19, while others20,21 have
not observed such a correlation. In the present study, no
correlation was identified between expression of c-erbB-2
and the TNM staging system. In other words, it was found
that positivity for this protein was not related to the grade
of the disease, contrary to the findings of some authors
cited above. The same can be seen in relation to the protein
E-cadherin. Some authors have obtained results that
demonstrate a correlation between the presence of this
protein and the more advanced stages of the disease 15,16,
while others were unable to detect such a correlation 13,17.
In the present study, as in the case of c-erbB-2, no correlation
was observed between the expression of E-cadherin and
the TNM staging. In other words, the loss of expression of
this protein was unrelated to the more advanced stages of
the disease. In the present study, in relation to the degree
of cell differentiation, there was a predominance of patients
with grade I tumors (well differentiated) and grade II tumors
(moderately differentiated), while grade III (undifferentiated)
was observed in only two patients. There are studies in the
literature that have detected correlations of the proteins c-
erbB-222 and E-cadherin23 with the degree of tumor
differentiation. However, in the present study, no such
correlation with the degree of cell differentiation was
identified, which may have resulted from the small number
of cases of undifferentiated tumors. No studies were found
in the literature that reported any relationship between these
two markers and the relapse rates for neoplastic disease in
colorectal adenocarcinoma. Likewise, the present study did
not show a statistically significant association between the
proteins studied and tumor relapse. Some authors have
observed a correlation between disease-free interval and
the expression of c-erbB-224 and E-cadherin 16. In the present
study, no correlation was identified between the expression
of the tumor markers studied and the disease-free interval.
Nor was there a correlation between positivity for c-erbB-2
and negativity for E-cadherin, a situation in which it would
be expected that there would be an increase in the invasive
potential of the tumor, according to the understanding of
carcinogenesis. Studies evaluating the association between
the expression of c-erbB-2 and survival have shown
controversial results. Some studies have demonstrated
reduced survival among patients with immunohistochemical
hyperexpression of the protein c-erbB-219,24, and also in
relation to reduced expression of E-cadherin, in colorectal
cancer patients25. In other studies, however, no association
has been detected between prognosis and the expression
of the protein c-erbB-221 or, furthermore, between prognosis
and the absence of the protein E-cadherin17. Similarly, the
present study did not present any statistically significant
association between the expression of these proteins and
survival, either separately or together. Some studies in the
literature have been able to find a significant correlation
between increased expression of the protein c-erbB-2 and
mortality 24, and also between the absence of E-cadherin
expression and mortality16. However, in the present study,
just as for the other clinical variables studied, the tumor
markers c-erbB-2 and E-cadherin did not correlate with
mortality among the patients studied. The first resultant
implication of the present study is that new investigations
into tumor markers must be made, with the objective of
contributing towards the knowledge of carcinogenesis.
Despite not finding a correlation for the tumor markers c-
erbB-2 and E-cadherin with the staging and prognosis of
colorectal carcinoma in the present study, positivity rates
similar to those reported in the literature were found. This
demonstrates the reliability of the results obtained and it
can therefore be inferred that this study makes a valid
contribution to the literature. Correlations between single
tumor markers and the prognosis for colorectal cancer do
not appear to be encouraging. We believe that research
into such correlations should not involve single tumor
markers but, rather, this research should be done through a
panel of markers. The choice of these markers should be
based both on the understanding of carcinogenesis and
also on their clinical importance in the prognosis of patients
with colorectal cancer.
Conclusion
The tumoral expression of c-erbB-2 and E-cadherin did
not demonstrate a correlation with the staging and degree
of cell differentiation, and it did not present prognostic value
regarding disease recurrence, disease-free interval, survival
and specific mortality among patients with colorectal
adenocarcinoma.
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